Cardiac Output and Recovery Time

NAEnrolling by invitationINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Residual Neuromuscular Blockade
Interventions
DEVICE

TetraGraph

FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.

Trial Locations (1)

32223

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER